Create new account



Books / Proceedings / Conference presentations

We were cited


Peer-reviewed papers

Patel N, Wiśniowska B, Polak S. Virtual thorough QT (TQT) trial - extrapolation of in vitro cardiac safety data to in vivo situation using multi-scale physiologically based ventricular cell-wall model exemplified with tolterodine and fesoterodine. AAPS J, 2018, accepted for publication.

Tylutki Z, Mendyk A, Polak S. Physiologically Based Pharmacokinetic - Quantitative Systems Toxicology and Safety (PBPK-QSTS) Modeling Approach Applied to Predict the Variability of Amitriptyline Pharmacokinetics and Cardiac Safety in Populations and in Individuals. Journal of Pharmacokinetics and Pharmacodynamics, 2018, accepted for publication.

Mikkelsen C, Jornil J, Andersen L, Hasselstrom J, Polak S. Utilizing Postmortem Drug Concentrations in Mechanistic Modeling and Simulation of Cardiac Effects: A Proof of Concept Study with Methadone. Toxicology Mechanisms and Methods, 2018, doi:

Wiśniowska B, Polak S. Drug - physiology interaction and its influence on the QT prolongation - mechanistic modeling study. Journal of Pharmacokinetics and Pharmacodynamics, 2018, doi:

Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, Hanna D. Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2018, doi:

Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, Hermann D, Polak S. Towards bridging translational gap in cardiotoxicity prediction: An application of Progressive Cardiac Risk Assessment Strategy in TdP risk assessment of Moxifloxacin. AAPS J, 2018, 20: 47.

Polak S, Wisniowska B, Mendyk A, Paclawski A, Szlek J. Quantitative assessment of the physiological parameters influencing QT interval response to medication: application of computational intelligence tools. Computational and Mathematical Methods in Medicine, 2018, Article ID 3719703.

Tuszynski PK, Polak S, Jachowicz R, Mendyk A. From in vitro-in vivo relationship (IVIVR) towards in vitro-in vivo extrapolation (IVIVE): A case study of pulmonary delivery systems. Dissolution Technologies, 2017, 24(4): 32-35.

Tylutki Z, Mendyk A, Polak S. Mechanistic Physiologically Based Pharmacokinetic (PBPK) model of the heart accounting for inter-individual variability - development and performance verification. Journal of Pharmaceutical Sciences, 2018, 107: 1167-1177.

Patel N, Wisniowska B, Jamei M, Polak S. Real patient and its virtual twin: Application of quantitative systems toxicology modelling in the cardiac safety assessment of citalopram. AAPS J, 2018, 20: 6.

Wisniowska B, Lisowski B, Kulig M, Polak S. Drugs interaction at hERG channel - in vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models. Journal of Applied Toxicology, 2018, 38: 450-458.

Wisniowska B, Tylutki Z, Polak S. Humans Vary, So Cardiac Models Should Account For That Too!. Friontiers in Physiology, 2017, 8: 700.

Wisniowska B, Tylutki Z, Polak S. Thorough QT (TQT) studies: Concordance with torsadogenesis and evolving cardiac safety testing paradigm. Drug Discovery Today, 2017, 22(10): 1460-1465.

Tylutki Z, Polak S. A four-compartment PBPK heart model accounting for cardiac metabolism - model development and applicationNature Scientific Reports, 2017, Scientific Reports 7, Article number: 39494.

Abbasi M, Patel N, Small B, Jamei M, Polak S. Early assessment of pro-arrhythmic risk of drugs using the in vitro data and single cell based in silico models: proof of concept Toxicology Mechanisms and Methods, 2017, 27(2):88-99.

Wisniowska B, Polak S. So am I or am I not proarrhythmic? Comparison of various classifications of drugs TdP propensity. Drug Discovery Today, 2017,22(1):10–16.

Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and QT prolongation Current Pharmacology Reports, 2016,2(6): 339-344.

Wisniowska B, Polak S. Virtual clinical trial towards polytherapy safety assessment – combination of PBPK/PD based modelling and simulation approach with DDIs involving terfenadine as an example. Journal of Pharmaceutical Sciences, 2016,105(11): 3415-3424.

Tylutki Z, Polak S, Wisniowska B. Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling & Simulations. Current Pharmacology Reports, 2016,2(14): 171-177.

Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacology and Toxicology, 2016,17(12).

Tylutki Z, Polak S. The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study. Bio-Algorithms and Med-Systems, 2016, 12(1):33-38.

Badyra B, Lisowski B, Polak S, Kudolo J, Wiśniowska B. How in vitro influences in silico utilized for the prediction of in vivo — pilot study of the drug-induced pro-arrhythmic potency prediction. Folia Medica Cracoviensia, 2015,LV(4): 5-19.

Mendyk A, Güres A, Jachowicz R, Szlęk J, Polak S, Wisniowska B, Kleinebudde P. From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks (ANNs) and Genetic Programming (GP). Computational and Mathematical Methods in Medicine, 2015, Article ID 863874.

Culen M, Tuszyński PK, Polak S, Jachowicz R, Mendyk A, Dohnal J. Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from ‘‘Golem’’: A Novel Apparatus). BioMed Research International, 2015, Article ID 328628.

Polak S, Pugsley MK, Stockbridge N, Garnett C, Wisniowska B. Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS Journal, 2015; 17(4): 1025-1032.

Tylutki Z, Polak S. Plasma vs. heart tissue concentration in humans – literature data analysis of drugs distribution. Biopharmaceutics and Drug Disposition, 2015; 36(6): 337–351.

Glinka A, Polak S. QTc modification after risperidone administration – insight into the mechanism of action with use of the modeling and simulation at the population level approachToxicology Mechanisms and Methods, 2015; 25(4): 279-286.

Wisniowska B, Mendyk A, Szlęk J, Kołaczkowski M, Polak S. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents. Journal of Applied Toxicology, 2015; 35(9): 1030–1039.

Mishra H, Polak S, Jamei M, Rostami-Hodjegan A. Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.  CPT Pharmacometrics Syst. Pharmacol., 2014; 3, e130.

Fijorek K, et al. Model of the distribution of diastolic left ventricular posterior wall thickness in healthy adults and its impact on the behavior of a string of virtual cardiomyocytes. Journal of Cardiovascular Translational Research, 2014; 7(5): 507-517.

Fijorek K, Püsküllüoglu M, Tomaszewski R, Tomaszewska D, Glinka A, Polak S. Serum potassium, sodium and calcium levels in healthy individuals – literature review and data analysis. Folia Medica Cracoviensia, 2014; LIV(1): 53-70.

Glinka A, Polak S. The Effects of Six Antipsychotic Agents on QTc - an attempt to mimic clinical trial through simulation including variability in the population. Computers in Biology and Medicine, 2014; 7:20-26.

Wisniowska B, Mendyk A, Fijorek K, Polak S. Computer-based prediction of the drug proarrhythmic effect - problems, issues, known and suspected challenges Europace, 2014, 16:724-735.

Polak S, Wisniowska B, Fijorek K, Glinka A, Mendyk A. In vitro - in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014; 19:275-281.

Glinka A, Polak S. An analysis of cardiomyocyte electrophysiology in the presence of hERG gene mutations. Bio-Algorithms and Med-Systems, 2013; 9(3):135-140.

Fijorek K, Püsküllüoglu M, Polak S. Circadian models of serum potassium, sodium and calcium concentrations in healthy individuals, and their application to cardiac electrophysiology simulations at individual levelComputational and Mathematical Methods in Medicine, 2013; Article ID 429037, 8 pages, 2013. doi:10.1155/2013/429037.

Mendyk A, Tuszyński P, Polak S, Jachowicz R. In vitro-in vivo relationship (IVIVR) generalized model based on artificial neural networksJournal of Drug Design, Development and Therapy, 2013;7:223-232.

Fijorek K, Patel N, Klima Ł, Stolarz-Skrzypek K, Kawecka-Jaszcz K, Polak S. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case studyTheoretical Biology and Medical Modelling, 2013;10:7.

Polak S. In vitro to human in vivo translation – pharmacokinetics and pharmacodynamics of quinidineALTEX, 2013;3(30):309-318.

Glinka A, Polak S. Wild type and K897T polymorphisms of the hERG gene: modeling the AP in Caucasians. Bioinformation, 2012;8(22):1062-1065.

Polak S, Wisniowska B, Glinka A, Polak M. - data describing the chemicals triggered in vitro cardiac ionic channels inhibitionBMC Pharmacology and Toxicology, 2012;13(6).

Wisniowska B, Mendyk A, Fijorek K, Glinka A, Polak S. Predictive model for the L-type channel inhibition - multichannel block in QT prolongation risk assessmentJournal of Applied Toxicology, 2012;32(10):858-866.

Polak S, Fijorek K. Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment - analysis of the age - cardiomyocytes electric capacitance dependence. Journal of Cardiovascular Translational Research, 2012;5(3):321-332.

Polak S, Wisniowska B, Glinka A, Fijorek K, Mendyk A. Slow delayed rectifying potassium current (IKs) – analysis of the in vitro inhibition data and predictive model developmentJournal of Applied Toxicology, 2013;33(8):723-739.

Polak S, Fijorek K, Glinka A, Wisniowska B, Mendyk A. Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessment. Toxicology Mechanisms and Methods, 2012;22(1):31-40.

Fijorek K, Fijorek D, Wisniowska B, Polak S. BDTcomparator: a program for comparing binary classifiersBioinformatics, 2011;27(24):3439-3440.

Fijorek K, Fijorek D. The effectiveness of best subset variable selection in Firth logistic regressionApplied Informatics Methods, 2012;2(27):15-24.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. The open-access dataset for in silico cardiotoxicity prediction systemBioinformation, 2011;6(6):244-245.

Polak S, Wisniowska B, Ahamadi M, Mendyk A. Prediction of the hERG potassium channel inhibition potential with use of Artificial Neural NetworksApplied Soft Computing, 2011;11(2):2611-2617.

Wisniowska B, Mendyk A, Polak M, Szlek J, Polak S. Random Forest based assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing. Bio-Algorithms and Med-Systems, 2010;6(12):131-136.

Wisniowska B, Polak S. hERG in vitro interchange factors - development and verification. Toxicology Mechanisms and Methods, 2009;19(4):278-284.

Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs cardiotoxic properties. Journal of Applied Toxicology, 2009;29(3):183-206.


Technical reports

Polak S, Fijorek K, Püsküllüoğlu M, Glinka A, Tomaszewska D, Tomaszewski R. Literature review of the serum potassium, sodium and calcium levels in healthy individualsTechnical Note, 2013; 001.